Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01782001
Other study ID # AMANI
Secondary ID
Status Completed
Phase Phase 3
First received January 27, 2013
Last updated January 30, 2013
Start date March 2009
Est. completion date November 2009

Study information

Verified date January 2013
Source Kintampo Health Research Centre, Ghana
Contact n/a
Is FDA regulated No
Health authority Ghana : Food and Drugs Board
Study type Interventional

Clinical Trial Summary

The purpose of this study was to determine whether young children receiving Vitamin A and Zinc supplements will have a lower incidence of symptomatic malaria than similar children receiving vitamin A supplements alone.


Description:

The aim of our study was to determine the impact of the combination of vitamin A and zinc supplements on malaria morbidity in young children. The primary objective was to determine the effect of vitamin A alone vs. vitamin A and zinc supplements on the incidence of clinical malaria. The specific objectives were to determine the effect of vitamin A alone vs. vitamin A and zinc supplements on changes in anthropometric measurements specifically weight and length/height and to assess the effect of the study interventions on the incidence of anemia, diarrhea and pneumonia. It also assessed the tolerability of the supplements and determined the change in zinc status by measuring plasma zinc concentration using atomic absorption spectrometry before and at the end of the intervention. The study also determined the change in vitamin A status as assessed by the modified relative dose response (MRDR) test during and at the end of the intervention.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date November 2009
Est. primary completion date November 2009
Accepts healthy volunteers No
Gender Both
Age group 6 Months to 24 Months
Eligibility Inclusion Criteria:

- Children aged 6 - 24 months

- Child's guardian is willing to provide informed consent

- Child's family plans to remain resident in the study areas during the study period

Exclusion Criteria:

- Clinical evidence of vitamin A deficiency

- Severe acute malnutrition

- Severe illness

- Child aged <6 months or >24 months

- Receipt of vitamin A supplement within the last three months

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
vitamin A
vitamin A with placebo
vitamin A and zinc
combination of vitamin A and zinc supplements

Locations

Country Name City State
Ghana Kintampo Health Research Centre Kintampo Brong Ahafo

Sponsors (3)

Lead Sponsor Collaborator
Kintampo Health Research Centre, Ghana International Atomic Energy Agency, University of Wisconsin, Madison

Country where clinical trial is conducted

Ghana, 

Outcome

Type Measure Description Time frame Safety issue
Primary incidence of clinical malaria attacks 6 months No
Secondary changes in weight and height/length Enrollment and end of supplementation baseline and 6 months No
Secondary changes in vitamin A and zinc nutritional status within and between the groups enrollment and end of supplementation baseline and 6 months No
Secondary change in prevalence of anemia enrollment and end of supplementation baseline and 6 months No
Secondary the incidence of diarrhea and pneumonia 1 time/week, enrollment to end, total:24 1 time per week up to 6 months No
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Completed NCT02315690 - Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland Phase 3